Evry, France, June 8th, 2017 - Yposkesi, the first French pharmaceutical company to develop and manufacture gene and cell therapy products for rare diseases, created by AFM-Téléthon and the SPI fund managed by Bpifrance, announced today its participation to BIO International Convention to be held from June 19 to 22, 2017 in San Diego, United States. The company represented by Frédéric Revah and Alain Lamproye, respectively President and CEO, will be located at booth 3217 on the France Pavilion (Business France).
Every year, BIO International Convention gathers in the United States several thousands of biotechnology and pharmaceutical companies. It highlights major achievements of the biotechnology industry in health, food industry and environment.
For meeting requests, please send an email to contact@yposkesi.com.
ABOUT YPOSKESI
Yposkesi (from the Greek Yposchesi, meaning ‘promise’) is the first French company to develop and produce gene and cell therapy products. Created in November 2016 by AFM-Téléthon and by the SPI fund managed by Bpifrance, this new company aims to make the first treatments available to patients and market them at a fair and controlled price, in accordance to the commitment made by its founders. Located in Evry (Essonne, France), this industrial platform is made up of more than 130 experts in bioproduction and has a first production building covering 5,000 m2. It is aiming at European leadership and, with this objective, by 2021 will bring together nearly 300 engineers, pharmacists, technicians and experts in three production buildings totaling 13,000 m2. It will thus meet the needs of AFM-Téléthon laboratories (Généthon and CECS/I-Stem), as well as those of academic and industrial biotechnology organizations, for clinical trials or post-MA (Marketing Authorization) distribution.
For more information, please visit our website at: www.yposkesi.com
